Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study) (PICCOLA)
|ClinicalTrials.gov Identifier: NCT00485056|
Recruitment Status : Completed
First Posted : June 12, 2007
Last Update Posted : August 9, 2016
|Condition or disease||Intervention/treatment||Phase|
|Diabetes||Drug: Pioglitazone||Phase 4|
The prevalence of diabetes mellitus and impaired glucose tolerance are nearing epidemic proportions in developed societies. For example in the USA >16 million individuals have diabetes and this number is predicted to double over the next two decades. Diabetes is a major risk factor for death and disability, primarily from cardiovascular disease (CVD).
The mechanisms of how diabetes increases the risk of developing CVD are not fully understood. It is evident from previous studies that diabetes has an adverse effect on both artery and heart function. What is emerging from recent studies is that it is likely that these proven dysfunctions in the arteries and heart interact to increase the risk of CVD.
Insulin-sensitizing agents, such as Pioglitazone, may have a beneficial effect on heart and artery function. This study aims to further our understanding of the effect of these agents on heart and artery using a novel, sensitive, non-invasive scanning technique to investigate the effects of this group of drugs on heart and artery function.
This is a prospective double-blind randomised crossover study comparing the insulin-sensitizing drug, Pioglitazone with a placebo in 24 volunteers. Following a >1 week run-in period subjects will be randomised double-blind to 1 of 2 treatment sequences. Subjects will either receive the active drug (Pioglitazone 45mg/day) for a 12 week period, followed by a 2 week washout and then the placebo drug for 12 weeks OR they will receive the placebo drug for 12 weeks, followed by the 2 week washout and 12 weeks of the active drug (Pioglitazone 45mg/day).
This design was chosen to test the null hypothesis that the active drug will have no effect on diastolic heart function. The use of a placebo is essential to ensure that any benefits found can be attributed to the active drug. The design also allows us to minimise the number of subjects needed and is the gold standard approach to avoid observer bias.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Pioglitazone on Cardiac Function and Large Arteries (PICCOLA)|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||April 2010|
|Actual Study Completion Date :||April 2010|
Placebo Comparator: Placebo
Active Comparator: Pioglitazone
Pioglitazone 45mgs daily
- The primary endpoint will be the TDI E' ratio which is the relatively preload independent measure of ventricular diastolic function. [ Time Frame: 26 weeks ]
- E/E' measured by TDI (a non-invasive measure of preload). [ Time Frame: 26 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00485056
|International Centre for Circulatory Health|
|London, United Kingdom, W2 1PG|
|Principal Investigator:||Alun D Hughes, phd||Imperial College London|